1-Year Outcomes of Thromboendarterectomy vs Endovascular Therapy for Common Femoral Artery Lesions CAULIFLOWER Study Results

被引:19
|
作者
Nakama, Tatsuya [1 ]
Takahara, Mitsuyoshi [2 ]
Iwata, Yo [3 ]
Fujimura, Naoki [4 ]
Yamaoka, Terutoshi [5 ]
Suzuki, Kenji [6 ]
Obunai, Kotaro [1 ]
机构
[1] Tokyo Bay Med Ctr, Dept Cardiol, 3-4-32 Todaijima, Urayasu, Chiba 2790001, Japan
[2] Osaka Univ, Dept Diabet Care Med, Grad Sch Med, Osaka, Japan
[3] Funabashi Municipal Med Ctr, Heart & Vasc Inst, Dept Cardiol, Funabashi, Chiba, Japan
[4] Tokyo Saiseikai Cent Hosp, Dept Vasc Surg, Tokyo, Japan
[5] Matsuyama Red Cross Hosp, Dept Vasc Surg, Matsuyama, Ehime, Japan
[6] Tokyo Saiseikai Cent Hosp, Dept Cardiol, Tokyo, Japan
关键词
common femoral artery; endovascular therapy; thromboendarterectomy; ENDARTERECTOMY; SURGERY;
D O I
10.1016/j.jcin.2022.03.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Thromboendarterectomy (TEA) is the gold-standard treatment for common femoral artery (CFA). However, because of its low invasiveness and short hospitalization duration, CFA endovascular therapy (EVT) is performed in real-world practice. However, the clinical benefits and appropriate target population for CFA EVT remain unclear. OBJECTIVES The aims of this study were to compare the clinical outcomes of TEA with those of EVT in patients with symptomatic CFA diseases and to identify the adequate target population for CFA EVT. METHODS A total of 1,193 consecutive patients who underwent EVT (n = 761) or TEA (n = 432) for CFA were identified and retrospectively reviewed from a registry of 66 institutions. The primary outcome was 1-year primary patency compared between EVT and TEA using propensity score matching. An interaction analysis was performed to explore the appropriate target population for CFA EVT. RESULTS After propensity score matching, the 1-year primary patency rate was significantly higher in the TEA group (82.3% vs 96.6%; P < 0.001), whereas perioperative complications were more frequently observed in the TEA group (P = 0.047). Nonambulatory status attenuated the HR of EVT vs TEA for restenosis risk (P = 0.021), whereas the presence of nodular calcification significantly increased the HR (P = 0.040). In the EVT subgroup analysis for restenosis risk, stent use showed the lowest HR compared with plain balloon angioplasty and drug-coated balloon angioplasty (P < 0.001). CONCLUSIONS TEA showed superior 1-year patency compared with EVT in a nationwide multicenter study. Nonambulatory status attenuated the superiority, whereas the presence of nodular calcification enhanced it. (C) 2022 by the American College of Cardiology Foundation.
引用
收藏
页码:1453 / 1463
页数:11
相关论文
共 23 条
  • [1] Results of common femoral artery thromboendarterectomy evaluation of a traditional surgical management in the endovascular era
    Wieker, Carola Marie
    Schoenefeld, Eva
    Osada, Nani
    Luehrs, Christina
    Beneking, Roland
    Torsello, Giovanni
    Boeckler, Dittmar
    JOURNAL OF VASCULAR SURGERY, 2016, 64 (04) : 995 - 1001
  • [2] An Overview of the Treatment of Symptomatic Common Femoral Artery Lesions with a Focus on Endovascular Therapy
    Shammas, Nicolas W.
    Doumet, Amanda Abi
    Karia, Rusina
    Khalafallah, Rommy
    VASCULAR HEALTH AND RISK MANAGEMENT, 2020, 16 : 67 - 73
  • [3] Lesion Characteristics Associated with Loss of Primary Patency After Endovascular Therapy for Common Femoral Artery Lesions
    Yamauchi, Yasutaka
    Takahara, Mitsuyoshi
    Iwata, Yo
    Suzuki, Kenji
    Fujimura, Naoki
    Yamaoka, Terutoshi
    Miyamoto, Akira
    Nakama, Tatsuya
    CAULIFLOWER Study Investigators
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2023, 46 (03) : 310 - 316
  • [4] Impact of Platelet Reactivity on 1-Year Clinical Outcomes After Endovascular Therapy for Femoropopliteal Lesions
    Tsujimura, Takuya
    Iida, Osamu
    Takahara, Mitsuyoshi
    Tobita, Kazuki
    Kawasaki, Daizo
    Fujihara, Masahiko
    Sasaki, Sinya
    Yokoi, Hiroyoshi
    Suzuki, Kenji
    Mano, Toshiaki
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 215 : 58 - 61
  • [5] Lesion Characteristics Associated with Loss of Primary Patency After Endovascular Therapy for Common Femoral Artery Lesions
    Yasutaka Yamauchi
    Mitsuyoshi Takahara
    Yo Iwata
    Kenji Suzuki
    Naoki Fujimura
    Terutoshi Yamaoka
    Akira Miyamoto
    Tatsuya Nakama
    CardioVascular and Interventional Radiology, 2023, 46 : 310 - 316
  • [6] Endovascular treatment with interwoven nitinol stent for common femoral artery lesions: 2-year outcomes of a single center experience
    Suwanruangsri, Veera
    Bokerd, Surakiat
    Chanchitsopon, Virapat
    Jowcharoen, Sirakarn
    VASCULAR, 2025, 33 (01) : 19 - 25
  • [7] Two-Year Outcomes of Endovascular Interventions of the Common Femoral Artery: A Retrospective Analysis From Two Medical Centers
    Shammas, Nicolas W.
    Shammas, Gail A.
    Karia, Rusina
    Khalafallah, Rommy
    Jones-Miller, Sue
    Shammas, Andrew N.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2021, 24 : 72 - 76
  • [8] Atherectomy-assisted endovascular therapy versus open repair for atherosclerotic common femoral artery disease: The multicenter ARISTON study
    Korosoglou, Grigorios
    Lee, Jason T.
    Andrassy, Martin
    Kotelis, Drosos
    Usai, Marco, V
    D'Oria, Mario
    Coscas, Raphael
    Troisi, Nicola
    Nasr, Bahaa
    Saratzis, Athanasios
    Antoniades, Solon
    Donas, Konstantinos P.
    ARISTON Collaborative
    VASCULAR MEDICINE, 2025, : 170 - 182
  • [9] 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery) Predictors of Restenosis
    Iida, Osamu
    Takahara, Mitsuyoshi
    Soga, Yoshimitsu
    Nakano, Masatsugu
    Yamauchi, Yasutaka
    Zen, Kan
    Kawasaki, Daizo
    Nanto, Shinsuke
    Yokoi, Hiroyoshi
    Uematsu, Masaaki
    JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (08) : 1105 - 1112
  • [10] The RANGER II superficial femoral artery trial: 1-year results of the long lesion cohort
    Schroe, Herman
    Sachar, Ravish
    Keirse, Koen
    Soga, Yoshimitsu
    Brodmann, Marianne
    Rao, Vikram
    Werner, Martin
    Holden, Andrew
    Lopez, Louis
    Krishnan, Prakash
    Diaz-Cartelle, Juan
    VASCULAR MEDICINE, 2022, 27 (05) : 457 - 465